Investigating how a specific protein affects immune cell function during lung injury from influenza.
Official title: The role of epigenetic regulator UHRF1 in stability of induced regulatory T-cell function during influenza A virus-induced lung injury
Funded at Northwestern University at Chicago · NIH-11045008 · Data updated 2026-11-12
This study is looking at how a protein called UHRF1 helps keep certain immune cells working well, which is important for healing the lungs after serious infections like the flu, and it aims to find better ways to treat patients with severe lung injuries.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | March 1, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $86,488 |
| NIH project number | 5F32HL162418-03 |
| Project ID | NIH-11045008 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing severe respiratory distress or pneumonia due to viral infections, particularly influenza.
✕Less likely to help
Patients with non-viral causes of respiratory distress or those who do not have significant immune system involvement may not benefit from this research.
What this research studies
This research focuses on understanding the role of the UHRF1 protein in maintaining the function of regulatory T-cells, which are crucial for controlling inflammation and promoting healing in the lungs after injury caused by influenza. The study aims to explore the mechanisms that affect the stability of these immune cells, particularly in the context of severe viral pneumonia and acute respiratory distress syndrome (ARDS). By examining how these cells can be effectively utilized in therapies, the research seeks to improve treatment outcomes for patients suffering from severe lung injuries.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies for patients with severe lung injuries caused by influenza and other viral infections.
How similar studies have gone: Previous research has shown promising results in using regulatory T-cells for therapeutic purposes, indicating that this approach has potential for success.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Joudi, Anthony — Northwestern University at Chicago
- Study coordinator: Joudi, Anthony
Related research
Other NIH-funded projects on the same topics.
-
Creating vaccines for influenza and other infectious diseases
This study is all about creating new vaccines to help protect people from the flu and other infections, so patients can look forward to better options for staying healthy.
-
Creating vaccines for human trials against influenza and other infectious diseases
This study is working on creating new vaccines to help protect people from flu and other infectious diseases, including those that could be used in harmful situations, so that everyone can have safer and more effective options to stay healthy.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Surveillance and preparedness for flu and other respiratory pathogens in Kenya
A US-based research grant aims to improve how Kenya detects and prepares for influenza and other respiratory diseases to protect people there and global health.
-
Enhanced Seasonal Influenza Vaccine Targeting Shared and Variable Viral Antigens
A new DNA-based influenza vaccine approach aims to provide both precise protection against circulating strains and broader defense against unexpected strains.
-
How the immune system responds to flu shots and flu infection
This project looks at how adults' immune systems react after flu shots or when they catch the flu to find why some people get better protection than others.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.